Space Mirrors and AI Drug Credit: The Latest Tech Developments

Reflect Orbital is preparing to launch an ambitious test satellite that will deploy a large mirror in orbit, aiming to harness sunlight and beam it back to Earth on demand. This innovative technology is touted for its potential to provide energy for solar panels, assist in emergency scenarios, and enhance military operations. However, a recent study raises alarms about the unintended consequences of such bright beams, which could illuminate the night sky as brightly as 10,000 full moons, potentially disrupting wildlife and aviation safety.

The company envisions a future where up to 50,000 satellites could reflect sunlight, but experts are concerned about the extensive light pollution that could result. The implications for natural ecosystems and human activities during nighttime are significant, sparking a heated debate about the balance between technological advancement and environmental preservation.

In a different realm of technology, the question of intellectual property rights in the age of artificial intelligence is becoming increasingly complex. Insilico Medicine recently announced it had discovered a promising drug for pulmonary fibrosis through its AI models, claiming the molecule was "discovered by" the AI. However, when it came to filing a patent, the company cited five human inventors, completely excluding the AI from the credit.

This situation highlights a crucial gap in current intellectual property law, which only recognizes human inventors, regardless of the role AI plays in the creative process. As AI continues to evolve and contribute significantly to drug design, the legal framework may need to adapt to address these modern challenges regarding ownership and credit.

As AI-generated drug designs proliferate, the distinction between human and machine contributions to invention could blur, raising critical questions about authorship in innovation.

Source: www.technologyreview.com